Fresenius SE & Co. KGaA (FRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fresenius SE & Co. KGaA (FRE) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€756.00 Million ≈ $883.84 Million USD) by net assets (€19.27 Billion ≈ $22.53 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Fresenius SE & Co. KGaA to measure how many days the company can operate on defensive assets alone.
Fresenius SE & Co. KGaA - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Fresenius SE & Co. KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fresenius SE & Co. KGaA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fresenius SE & Co. KGaA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ABN AMRO BK.UNSP.ADR/1
F:AB2A
|
N/A |
|
BK MANDIRI (PE).ADR/20 ON
F:PQ90
|
0.295x |
|
Bunge Limited
NYSE:BG
|
0.077x |
|
TechnipFMC PLC
F:1T1
|
0.099x |
|
Reddit, Inc.
NYSE:RDDT
|
0.091x |
|
Novonesis (Novozymes) A/S
CO:NSIS-B
|
0.015x |
|
First Solar Inc
NASDAQ:FSLR
|
-0.022x |
|
Sigma Healthcare Ltd
AU:SIG
|
0.065x |
Annual Cash Flow Conversion Efficiency for Fresenius SE & Co. KGaA (2002–2024)
The table below shows the annual cash flow conversion efficiency of Fresenius SE & Co. KGaA from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Fresenius SE & Co. KGaA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €20.29 Billion ≈ $23.72 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.121x | -46.81% |
| 2023-12-31 | €19.65 Billion ≈ $22.97 Billion |
€4.46 Billion ≈ $5.21 Billion |
0.227x | +74.03% |
| 2022-12-31 | €32.22 Billion ≈ $37.67 Billion |
€4.20 Billion ≈ $4.91 Billion |
0.130x | -24.85% |
| 2021-12-31 | €29.29 Billion ≈ $34.24 Billion |
€5.08 Billion ≈ $5.94 Billion |
0.173x | -31.11% |
| 2020-12-31 | €26.02 Billion ≈ $30.42 Billion |
€6.55 Billion ≈ $7.66 Billion |
0.252x | +56.91% |
| 2019-12-31 | €26.58 Billion ≈ $31.07 Billion |
€4.26 Billion ≈ $4.98 Billion |
0.160x | +7.19% |
| 2018-12-31 | €25.01 Billion ≈ $29.24 Billion |
€3.74 Billion ≈ $4.37 Billion |
0.150x | -17.45% |
| 2017-12-31 | €21.72 Billion ≈ $25.39 Billion |
€3.94 Billion ≈ $4.60 Billion |
0.181x | +9.57% |
| 2016-12-31 | €21.60 Billion ≈ $25.26 Billion |
€3.57 Billion ≈ $4.18 Billion |
0.165x | -5.77% |
| 2015-12-31 | €18.95 Billion ≈ $22.15 Billion |
€3.33 Billion ≈ $3.89 Billion |
0.176x | +9.78% |
| 2014-12-31 | €16.16 Billion ≈ $18.90 Billion |
€2.58 Billion ≈ $3.02 Billion |
0.160x | -5.34% |
| 2013-12-31 | €13.73 Billion ≈ $16.05 Billion |
€2.32 Billion ≈ $2.71 Billion |
0.169x | -8.83% |
| 2012-12-31 | €13.16 Billion ≈ $15.38 Billion |
€2.44 Billion ≈ $2.85 Billion |
0.185x | +16.05% |
| 2011-12-31 | €10.58 Billion ≈ $12.37 Billion |
€1.69 Billion ≈ $1.97 Billion |
0.160x | -26.10% |
| 2010-12-31 | €8.84 Billion ≈ $10.34 Billion |
€1.91 Billion ≈ $2.23 Billion |
0.216x | +6.47% |
| 2009-12-31 | €7.65 Billion ≈ $8.95 Billion |
€1.55 Billion ≈ $1.82 Billion |
0.203x | +31.20% |
| 2008-12-31 | €6.94 Billion ≈ $8.12 Billion |
€1.07 Billion ≈ $1.26 Billion |
0.155x | -60.16% |
| 2007-12-31 | €3.34 Billion ≈ $3.90 Billion |
€1.30 Billion ≈ $1.52 Billion |
0.388x | +14.48% |
| 2006-12-31 | €3.10 Billion ≈ $3.63 Billion |
€1.05 Billion ≈ $1.23 Billion |
0.339x | +20.70% |
| 2005-12-31 | €2.78 Billion ≈ $3.25 Billion |
€780.00 Million ≈ $911.90 Million |
0.281x | -47.07% |
| 2004-12-31 | €1.60 Billion ≈ $1.87 Billion |
€851.00 Million ≈ $994.91 Million |
0.531x | +119.88% |
| 2003-12-31 | €3.21 Billion ≈ $3.76 Billion |
€776.00 Million ≈ $907.23 Million |
0.241x | +16.70% |
| 2002-12-31 | €3.37 Billion ≈ $3.94 Billion |
€697.00 Million ≈ $814.87 Million |
0.207x | -- |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more